Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VSIR | Q9H7M9 | 4/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 11/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 8/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.33 |
| ▸ | CBLB | Q13191 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24818674 | 0.94 | VSIR (0.40) | VSIRS1PR1S1PR3CETPCBLB | |
| SCHEMBL24818892 | 0.90 | VSIR (0.36) | VSIRS1PR1S1PR3CETPCBLB | |
| SCHEMBL30152815 | 0.89 | VSIR (0.40) | VSIRS1PR1S1PR3CBLBHPGD | |
| SCHEMBL24820062 | 0.89 | VSIR (0.40) | VSIRS1PR1S1PR3CBLBHPGD | |
| SCHEMBL24819904 | 0.89 | VSIR (0.52) | VSIR | |
| SCHEMBL30152856 | 0.87 | VSIR (0.40) | VSIRS1PR1S1PR3HPGD | |
| SCHEMBL24821896 | 0.87 | VSIR (0.40) | VSIRS1PR1S1PR3HPGD | |
| SCHEMBL24819018 | 0.87 | VSIR (0.40) | VSIRS1PR1S1PR3CETPCBLB | |
| SCHEMBL24819924 | 0.87 | VSIR (0.37) | VSIRS1PR1S1PR3CETPCBLB | |
| SCHEMBL30152823 | 0.86 | VSIR (0.41) | VSIRS1PR1S1PR3CETPCBLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4359381-A1 | CBL-B MODULATORS AND USES THEREOF | Nimbus Clio, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2022272248-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2022-12-29 | — | — | WO | disclosed |